Maximus: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Maximus' website, https://www.maximustribe.com, FDA Establishment Identifier (FEI) 3032037948, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website: "Clinically studied ingredients." "Clinically studied to help patients…." "Proven to lose weight effectively" Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

2. 2

   “2. Your website claims that the compounded drug products it offers are sourced from "FDA approved pharmacies." Compounding facilities, including pharmacies and outsourcing facilities, are not "FDA-approved" or "FDA-licensed" entities. The FD&C Act does not establish an "FDA-approved" or "FDA-licensed" designation for pharmacies or outsourcing facilities.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

maximustribe.com returned a live storefront when we checked in August 2026, still operating under the Maximus name.

Two distinct claims got flagged here, and they cut differently: "clinically studied" / "proven to lose weight effectively" is the same overstated-efficacy pattern in the other letters on this page, but "sourced from FDA approved pharmacies" is a step further — FDA said there is no such designation at all, for any pharmacy. If a provider's marketing leans on "FDA-approved pharmacy" language, that phrase itself doesn't mean what it sounds like it means.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Maximus failed to respond.